Cargando…

Multicentre early experience with totally subcutaneous cardioverter-defibrillators in Poland

INTRODUCTION: Implantable cardioverter-defibrillators (ICD) have a strong position in the prevention of sudden death. Nowadays, the most commonly used high-energy cardiac devices are transvenous ICDs. A new technology of totally subcutaneous ICDs (S-ICD) was invented and recently introduced into cli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaczmarek, Krzysztof, Kempa, Maciej, Grabowski, Marcin, Tajstra, Mateusz, Sokal, Adam, Cygankiewicz, Iwona, Zwoliński, Radosław, Michalak, Marcin, Kowara, Michal, Budrejko, Szymon, Kurek, Anna, Wranicz, Jerzy K., Raczak, Grzegorz, Opolski, Grzegorz, Gąsior, Mariusz, Kowalski, Oskar, Ptaszyński, Paweł
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286329/ https://www.ncbi.nlm.nih.gov/pubmed/32542076 http://dx.doi.org/10.5114/aoms.2019.83817

Ejemplares similares

Subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death
por: Kempa, Maciej, et al.
Publicado: (2016)

A survey study of the use of a subcutaneous implantable cardioverter-defibrillator in various clinical scenarios by expert electrophysiologists in Poland
por: Kempa, Maciej, et al.
Publicado: (2023)

Initial experience with the subcutaneous implantable cardioverter-defibrillator with the real costs of hospitalization analysis in a single Polish center
por: Grabowski, Marcin, et al.
Publicado: (2019)

Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europe–Comparison of the Results of Multi-Center Registries
por: Kempa, Maciej, et al.
Publicado: (2021)

Implantation of additional subcutaneous array electrode reduces defibrillation threshold in ICD patients – preliminary results
por: Kempa, Maciej, et al.
Publicado: (2013)

One-Year Follow-Up of Patients Undergoing Transvenous Extraction of Pacemaker and Defibrillator Leads
por: Kempa, Maciej, et al.
Publicado: (2015)

The 18-fluorine-fluorodeoxyglucose positron-emission-tomography/computed tomography-guided treatment of prosthetic valve endocarditis
por: Sławiński, Grzegorz, et al.
Publicado: (2019)

Real-Life Inter-Rater Variability of the PRAETORIAN Score Values
por: Budrejko, Szymon, et al.
Publicado: (2022)

An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis
por: Wasiak, Michał, et al.
Publicado: (2023)

Systemic Brucellosis with Arrhythmogenic Cardiac Inflammatory Pseudotumor
por: Kaczmarek, Krzysztof, et al.
Publicado: (2022)

Application of Novel Technologies in Cardiac Electrotherapy to Prevent Complications
por: Budrejko, Szymon, et al.
Publicado: (2023)

Baseline intrinsic heart rate and response to ivabradine treatment in patients with inappropriate sinus tachycardia
por: Kaczmarek, Krzysztof, et al.
Publicado: (2019)

Transesophageal echocardiography guided transseptal puncture for atrial fibrillation ablation in a patient with a 30 mm atrial septal closure device
por: Sabiniewicz, Robert, et al.
Publicado: (2016)

Prevalence of Lyme Carditis in Patients with Atrioventricular Blocks
por: Kaczmarek, Krzysztof A., et al.
Publicado: (2022)

Subcutaneous Implantable Cardioverter Defibrillators for the Prevention of Sudden Cardiac Death: Pediatric Single-Center Experience
por: Wieniawski, Piotr, et al.
Publicado: (2022)

Increased risk of minor bleeding and antiplatelet therapy cessation in patients with acute coronary syndromes and low on-aspirin platelet reactivity. A prospective cohort study
por: Huczek, Zenon, et al.
Publicado: (2012)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
por: Jonik, Szymon, et al.
Publicado: (2022)

Implantable Cardioverter-Defibrillators in Poland Compared with other European Countries from the Patient’s Perspective: Insights from the EHRA Patient Survey
por: Januszkiewicz, Łukasz, et al.
Publicado: (2023)

Pathophysiology of Takotsubo Syndrome as A Bridge to Personalized Treatment
por: Budnik, Monika, et al.
Publicado: (2021)

Stress Echocardiography Protocol for Deciding Type of Surgery in Ischemic Mitral Regurgitation: Predictors of Mitral Regurgitation Recurrence following CABG Alone
por: Piatkowski, Radoslaw, et al.
Publicado: (2021)

NT-proBNP increase during stress echocardiography predicts significant changes in ischemic mitral regurgitation severity in patients qualified for surgical revascularization
por: Piątkowski, Radosław, et al.
Publicado: (2022)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement
por: Burban, Anna, et al.
Publicado: (2023)

Risk-benefit assessment of ivabradine in the treatment of chronic heart failure
por: Urbanek, Irmina, et al.
Publicado: (2014)

An Individualized Approach of Multidisciplinary Heart Team for Myocardial Revascularization and Valvular Heart Disease—State of Art
por: Jonik, Szymon, et al.
Publicado: (2022)

The Automatic External Cardioverter-Defibrillator
por: Martínez-Rubio, Antoni, et al.
Publicado: (2004)

Deactivation of implantable cardioverter-defibrillators
por: Wan, Darryl, et al.
Publicado: (2021)

Percutaneous Occlusion of the Left Atrial Appendage with Thrombus Irresponsive to Antithrombotic Therapy
por: Kaczmarek, Krzysztof, et al.
Publicado: (2021)

The subcutaneous implantable cardioverter-defibrillator should be considered for all patients with an implantable cardioverter-defibrillator indication
por: Tan, Jian Liang, et al.
Publicado: (2022)

Subcutaneous implantable cardioverter-defibrillator placement in a patient with a preexisting transvenous implantable cardioverter-defibrillator
por: Jazayeri, Mohammad-Ali, et al.
Publicado: (2017)

Defibrillation Testing of the Implantable Cardioverter Defibrillator: When, How, and by Whom?
por: Pires, Luis A
Publicado: (2007)

Predictors of Elevated Defibrillation Threshold with the Subcutaneous Implantable Cardioverter-defibrillator
por: Do, Khuyen, et al.
Publicado: (2017)

Electrophysiological features in patients with sinus node dysfunction and vasovagal syncope
por: Graff, Beata, et al.
Publicado: (2011)

Remote Monitoring of Implantable Cardioverter Defibrillator
por: Reynolds, Dwight W, et al.
Publicado: (2006)

The Subcutaneous Implantable Cardioverter-Defibrillator: Not For All
por: Nair, Krishnakumar, et al.
Publicado: (2014)

Programming implantable cardioverter/defibrillators and outcomes
por: Horlbeck, Fritz W., et al.
Publicado: (2015)

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy
por: Sanchez, Diego Jimenez, et al.
Publicado: (2018)

Implantation of Implantable Cardioverter Defibrillators in Kazakhstan
por: Begisbayev, Temirkhan, et al.
Publicado: (2022)

Characteristics of Cardiac Memory in Patients with Implanted Cardioverter-defibrillators: The Cardiac Memory with Implantable Cardioverter-defibrillator (CAMI) Study
por: Haq, Kazi T., et al.
Publicado: (2021)

Relation of multicenter automatic defibrillator implantation trial implantable cardioverter-defibrillator score with long-term cardiovascular events in patients with implantable cardioverter-defibrillator
por: Uslu, Abdulkadir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_63j0b9lm6mv8l3737jcs35u2eu